Visualizing Regional Lung Ventilation in Patients With Postacute-COVID-19

NCT ID: NCT05441657

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-14

Study Completion Date

2025-08-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a lack of data of spontaneous breathing patients with post-COVID-19 syndrome (PCS) examined by Electrical impedance tomography (EIT). We compare 100 patients with PCS with 50 healthy probands.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

When treating patients with dyspnoea, conventional diagnostic tools (computed tomography, spirometry, body plethysmography) often fail to detect pathological changes, making it difficult for the treating physician to choose an appropriate therapeutic approach. Therefore, it would be desirable to have an examination method that reveals the pulmonary changes in postacute Corona-Virus-Disease-2019 (COVID-19) syndrome (PCS) patients that remain hidden from other diagnostic procedures.

Electrical impedance tomography (EIT) is a non-invasive and radiation-free imaging technique that can show the regional ventilation of the lungs almost "in real-time" based on the changes in the electrical impedance of the thorax during inspiration and expiration. This method is based on the observation that the electrical conductivities of biological tissues vary considerably depending on their nature and functional state. Clinical questions in which the inhomogeneity of lung ventilation is to be analysed (e.g., under- or overinflation of individual lung areas, lung collapse, etc.) can be investigated particularly well with EIT since intrathoracic impedance changes correlate strongly with changes in regional lung ventilation.

Up to now, EIT has mainly been used as a monitoring method in intensive care medicine to adapt ventilation settings and other therapeutic measures to the individual needs of patients. In this field, the method has proven useful for obtaining an overview of the distribution of a respiratory volume in a transverse EIT slice, comparing different lung regions, identifying inhomogeneities and assessing regional ventilation during spontaneous breathing.

The aim of this case-control study is to use EIT data obtained during routine examinations of post-COVID patients to analyse whether patients with PCS show more distinct lung alterations than the control group. Maybe these lung alterations correlate with dyspnea most patients report subjectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventilatory Defect COVID-19 Post-acute COVID-19 Syndrome Electric Impedance Tomography Post-COVID-19 Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dyspnoeic patients with post-acute COVID-19 syndrome

100 patients with/without persisting dyspnea after COVID-19 disease were examined by Electric Impedance Tomography (EIT).

No interventions assigned to this group

control group

50 healthy volunteers with no lung disease were voluntarily examined by Electric Impedance Tomography.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* for control group: no current lung diseases, over 18 years old
* for patients with postacute COVID-19 syndrome: over 18 years, positive SARS-CoV-2-PCR

Exclusion Criteria

* heart pacemaker
* epilepsy
* BMI over 50
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jan-Christoph Lewejohann

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jan-Christoph Lewejohann

Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan-Christoph Lewejohann, Dr.med.

Role: STUDY_DIRECTOR

Jena University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jena university hospital

Jena, Thuringia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KIM-IV-EIT-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.